Analyst Ratings February 11, 2026

Jefferies Sticks With Buy on Hilton, Eyes $339 Price Target After Strong Q4 Results

Broker cites resilient business model and 2026 net unit growth outlook; upcoming earnings call commentary flagged as possible catalyst

By Leila Farooq HLT
Jefferies Sticks With Buy on Hilton, Eyes $339 Price Target After Strong Q4 Results
HLT

Jefferies has maintained a Buy rating on Hilton Worldwide (HLT) and set a $339 price target, calling the company’s recent report and guidance "modestly positive." The firm points to slight upside relative to consensus, an ongoing Net Unit Growth outlook for 2026, and strong fourth-quarter results that beat analyst expectations on both earnings and revenue.

Key Points

  • Jefferies reiterated a Buy rating on Hilton and set a $339.00 price target, citing a resilient business model.
  • Hilton's recent guidance was described as "modestly positive," and the company’s guidance came in modestly higher than consensus expectations.
  • Hilton reported Q4 adjusted EPS of $2.08 versus a $2.02 consensus and revenue of $3.09 billion versus an expected $2.99 billion; RevPAR growth was modest but bottom-line results were stronger than anticipated.

Jefferies has reaffirmed its Buy rating on Hilton Worldwide (NYSE: HLT), keeping a $339.00 price target and reiterating confidence in the hotel operator's underlying business model.

In its commentary, the firm described Hilton's recent report and guidance as "modestly positive" for the shares, and underscored its view that Hilton ranks among the strongest business models within its coverage universe across a range of economic scenarios.

Jefferies pointed to a modest upside in Hilton's results and noted that the company's guidance came in slightly above consensus expectations. The research house also highlighted Hilton's continued Net Unit Growth - NUG - outlook for 2026 as supportive of the company's expansion prospects.

Beyond the snapshot provided in guidance, Jefferies suggested that remarks made during Hilton's upcoming earnings call could be a "key driver" for upward movement in the stock, implying that investor reaction may hinge on management commentary and tone.

Separately, Hilton reported fourth-quarter results that topped analyst forecasts. The company posted adjusted earnings per share of $2.08, compared with a consensus estimate of $2.02. Revenue for the quarter reached $3.09 billion, outpacing the anticipated $2.99 billion. These outcomes point to a robust financial performance in the period.

Although revenue per available room - RevPAR - showed only modest growth, the stronger-than-expected bottom-line results were well received. Market watchers have been focused on metrics such as RevPAR and adjusted EPS because they are central to assessing Hilton's financial health. The recent earnings update indicates the company was able to deliver solid profitability even with only moderate RevPAR gains.

Taken together, Jefferies' reaffirmation and Hilton's reported quarter present a consistent picture: the broker sees a high-quality business model and constructive near-term indicators, while the company demonstrated the capacity to exceed analyst estimates on fundamental financial measures.

Risks

  • Modest RevPAR growth could constrain revenue momentum even as profitability exceeded expectations - this affects hospitality and travel sector revenue performance.
  • Market reaction may depend heavily on management commentary during Hilton's upcoming earnings call, creating short-term stock-price volatility in the hospitality and broader equities markets.
  • Guidance and near-term results only modestly exceeded consensus, which leaves limited margin for disappointment versus analyst expectations in the lodging sector.

More from Analyst Ratings

HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026